N/A N=13 Accuracy of Pulse Oximeters With Profound Hypoxia at Rest
Hypoxia
Primary: Accuracy of Sensor Oxygen Saturation by Arms Calculation — 0.86 percentage of RMS error
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Accuracy of Pulse Oximeters With Profound Hypoxia During Motion
Hypoxia
Primary: Accuracy of Sensor Oxygen Saturation by Arms Calculation — 1.0 percentage of RMS error
N/A N=30 Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention
Virtual Reality
Primary: Percentage of Participants Using Virtual Reality Software at 20 Minutes After Start — 15; 14 Participants — p=1.00
N/A N=28 Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
Photoaging
Primary: Mean Improvement in Photoaging Damage Appearance at 3 Months Post Treatment — 2.81 units on a scale
N/A N=505 A Community Wellness Program for Adults Living With Long-term Physical Disability
Physical Disability
Primary: Change in Self-reported Ability to Participate in Community Activities From Baseline to 6 Months — 2.49; 1.25; 0.09 score on a scale — p=<0.01
Phase 3 N=485 Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Ocular Hypertension · Glaucoma
Primary: Intra-Ocular Pressure — -9.67; -9.50 mmHg — p=0.453
N/A N=2,054 Using MC1R Genotype to Impact Melanoma Risk Behavior
Melanoma (Skin) · Squamous Cell Carcinoma · Squamous Cell Cancer
Primary: Weekday Sun Exposure - NHW - Baseline — 1.27; 1.30; 1.26; 1.29 Hours
Phase 3 N=660 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Diabetic Macular Edema · Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 — 8.67; 8.10…
Phase 2 N=71 Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Overall Survial Time — 18.3 months
N/A N=26 Islamic Trauma Healing: Feasibility Study
Post Traumatic Stress Disorder
Primary: PTSD Scale - Self-Report for DSM-5 (PDS-5; Foa et al., 2016) — 8.08 score on a scale
N/A N=416 Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Primary Effectiveness Endpoint — 130; 119 Participants — p=0.013
N/A N=217 Testing a Provider-Level Feedback Intervention to Optimize Postoperative Prescribing
Opioid Prescribing
Primary: Change in Opioid Prescribed Following the Intervention — 62.0; 58.8 Morphine Milligram Equivalents (MME) — p=0.010
Phase 3 N=56 A Trial to Improve Quality of Life in People With Cirrhosis
Cirrhosis
Primary: Short Form-8 Health Survey (SF-8) at 28 Days — 8.1; 6.55; 70.9; 63.84 score on a scale — p=0.6
Phase 3 N=39 Preoperative Alpha Blockade for Pheochromocytoma
Pheochromocytoma · Paraganglioma
Primary: Hemodynamic Instability — 14; 13 percentage of total operative time — p=.56
N/A N=52 Research on Improving Sleep During Pregnancy
Sleep · Pregnancy Related
Primary: Number of Participants With a Total Score Greater Than or Equal to 24 on the 8-item Client Satisfaction Questionnaire (CSQ-8) at 12 Weeks — 20 Participants